{
  "name": "Amgen",
  "slug": "amgen",
  "ticker": "AMGN",
  "fetched_at": "2026-02-03T12:37:07.573521+00:00",
  "news": [
    {
      "title": "As Amgen and Lilly Recommit, Puerto Rico Seeks To Regain Manufacturing Momentum - BioSpace",
      "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPbEdsUGZMNmtqODl2Q2pPR1hmVlVqVk1WcWVET1NZdktkRFVhREF4dVBSYXhWTWZxTldlQ2Fhblh2amVReXNRZDJ4UkdydWFOcHlGMDRlV29ZSXphdlY1RnNTaEFUVzRTeDg2N0dRSGVLMV92VU5aWEJWWXBsdDdLNmRKWE9NVEFQRGhPcE9hdnMwdmIzZjNySnJNNE1IUkZNV05ud01faTNLQTFUS1h0R3h3?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMisgFBVV95cUxPbEdsUGZMNmtqODl2Q2pPR1hmVlVqVk1WcWVET1NZdktkRFVhREF4dVBSYXhWTWZxTldlQ2Fhblh2amVReXNRZDJ4UkdydWFOcHlGMDRlV29ZSXphdlY1RnNTaEFUVzRTeDg2N0dRSGVLMV92VU5aWEJWWXBsdDdLNmRKWE9NVEFQRGhPcE9hdnMwdmIzZjNySnJNNE1IUkZNV05ud01faTNLQTFUS1h0R3h3?oc=5\" target=\"_blank\">As Amgen and Lilly Recommit, Puerto Rico Seeks To Regain Manufacturing Momentum</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioSpace</font>",
      "published": "2026-02-03T05:07:06+00:00",
      "source": "BioSpace"
    },
    {
      "title": "Amgen gives up on its once-prized eczema drug - BioPharma Dive",
      "link": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPV3NpQ3EtcEk3R1Ytdy1DX19ST1J1S2ZUS1FoS2R3MXVmYVpuVzlKdi1XZ2RqU0tfRFlDdjI2elhLd0dJUGtlYkJjYUVsQ3VwbUpDenlXVWlJRmhMbE4zUnVudkpHdU8wZTEwaE1BSjUzell0S09EMHk5RDdyTnpaRFF2TzdIeEMzMlY5ZU0xNTNCTHVSRVVmWUdjWjUtYlA2Q1dJellpb1BkN1ZGaWc?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMirgFBVV95cUxPV3NpQ3EtcEk3R1Ytdy1DX19ST1J1S2ZUS1FoS2R3MXVmYVpuVzlKdi1XZ2RqU0tfRFlDdjI2elhLd0dJUGtlYkJjYUVsQ3VwbUpDenlXVWlJRmhMbE4zUnVudkpHdU8wZTEwaE1BSjUzell0S09EMHk5RDdyTnpaRFF2TzdIeEMzMlY5ZU0xNTNCTHVSRVVmWUdjWjUtYlA2Q1dJellpb1BkN1ZGaWc?oc=5\" target=\"_blank\">Amgen gives up on its once-prized eczema drug</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioPharma Dive</font>",
      "published": "2026-01-30T17:12:48+00:00",
      "source": "BioPharma Dive"
    },
    {
      "title": "Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline” - Yahoo Finance UK",
      "link": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNdjRMUXJnemlkWDhQaWliTG14U2RuU2d4V3pheUNFTXlSMmZlbGNvM0RTb3V1QXkyZkd1TG5LNU5CbGl3MHBCenNkeUZGZTQyLVRBM1FPMi1EVTJ4N0t0bHpiczc4bnJMdThMNXdEd21pSXZQN091czBJbnZKWERjLWIwY1VMbGc?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihwFBVV95cUxNdjRMUXJnemlkWDhQaWliTG14U2RuU2d4V3pheUNFTXlSMmZlbGNvM0RTb3V1QXkyZkd1TG5LNU5CbGl3MHBCenNkeUZGZTQyLVRBM1FPMi1EVTJ4N0t0bHpiczc4bnJMdThMNXdEd21pSXZQN091czBJbnZKWERjLWIwY1VMbGc?oc=5\" target=\"_blank\">Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline”</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance UK</font>",
      "published": "2026-02-03T12:24:06+00:00",
      "source": "Yahoo Finance UK"
    },
    {
      "title": "Amgen exits $400M autoimmune pact after running vast program - Fierce Biotech",
      "link": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQX0JJNGxMMTVIY3FndkpvbkJ5WjNaWGhnb3BRNHVLTDk5aFhnM3o4WERSWUVSSTAycm4tTkhOZGhoVGVBVWZSeGpYZmlpNzc0anRrTlRDelh4ZVBYcndEajFLOGhSQlhEZ2VsQTNzRVFYRmhldVBrZVY4U0EtNkU0ZEhaOS1aVktVd0pndHZtR19rNFk3TEVsVkEydEktVzduWUZPOUNjdE9XSHRfbVRUMlRSdzdiaDZtTm5Z?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQX0JJNGxMMTVIY3FndkpvbkJ5WjNaWGhnb3BRNHVLTDk5aFhnM3o4WERSWUVSSTAycm4tTkhOZGhoVGVBVWZSeGpYZmlpNzc0anRrTlRDelh4ZVBYcndEajFLOGhSQlhEZ2VsQTNzRVFYRmhldVBrZVY4U0EtNkU0ZEhaOS1aVktVd0pndHZtR19rNFk3TEVsVkEydEktVzduWUZPOUNjdE9XSHRfbVRUMlRSdzdiaDZtTm5Z?oc=5\" target=\"_blank\">Amgen exits $400M autoimmune pact after running vast program</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Biotech</font>",
      "published": "2026-01-30T13:55:13+00:00",
      "source": "Fierce Biotech"
    },
    {
      "title": "CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns - Fierce Pharma",
      "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOSkQ1MlBselFFLWVvdDJKTl9iSGlHZVpUeXd2bTk1X0E4MVFlUGhfVzFuMkkwMDZENTNOYlIzSzBUQlhuRUc1R01EVmtwcmwyLV9acHhGcjdIYllmUHRKVVdyam80RGh1Qjlaclp2MXVBT3QzelFuaUV5OGNfbWw1MkF5NmdiNTNtcENpTXlBUzk0T3pqZ0NDRDdWVklWa1NRcldqZ1Zrckc1Z2RnN1NDS3M4cmZqRm1CTUN1RHVRN3ViOUk?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOSkQ1MlBselFFLWVvdDJKTl9iSGlHZVpUeXd2bTk1X0E4MVFlUGhfVzFuMkkwMDZENTNOYlIzSzBUQlhuRUc1R01EVmtwcmwyLV9acHhGcjdIYllmUHRKVVdyam80RGh1Qjlaclp2MXVBT3QzelFuaUV5OGNfbWw1MkF5NmdiNTNtcENpTXlBUzk0T3pqZ0NDRDdWVklWa1NRcldqZ1Zrckc1Z2RnN1NDS3M4cmZqRm1CTUN1RHVRN3ViOUk?oc=5\" target=\"_blank\">CHMP thumbs-up Novo's semaglutide for MASH, as Amgen gets Tavneos re-review on data integrity concerns</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Pharma</font>",
      "published": "2026-01-30T17:00:00+00:00",
      "source": "Fierce Pharma"
    },
    {
      "title": "Will Exiting Rocatinlimab Reshape Amgen's (AMGN) Immunology Focus and Broader R&D Narrative? - simplywall.st",
      "link": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOemgyV1lmbm1lTlRXazRtMVJUM0h3ZjhKekNrbVFCbkR1WHVBQjd5S3ZjdmdNSWpGdEptVVBZYzlDLVJwNVE4VHRPME1Demd3WGk5Z3EwRC1Vam5ITUdnVUtpNnk5eGRZeDZ2bnRlTURyRUxLQmZvT0k2X2t5VnotN0xpM0ViQTJwUWNjWW1faXJtVXVCQ29QLW1wQkxlSHFVZFpSUTdvNFo4NzV3MUZzQ1FSbEMwanR1c3dRZW5UTkxqSHFWbDh1SXhrckpYMU1GZkdkMVNB?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOemgyV1lmbm1lTlRXazRtMVJUM0h3ZjhKekNrbVFCbkR1WHVBQjd5S3ZjdmdNSWpGdEptVVBZYzlDLVJwNVE4VHRPME1Demd3WGk5Z3EwRC1Vam5ITUdnVUtpNnk5eGRZeDZ2bnRlTURyRUxLQmZvT0k2X2t5VnotN0xpM0ViQTJwUWNjWW1faXJtVXVCQ29QLW1wQkxlSHFVZFpSUTdvNFo4NzV3MUZzQ1FSbEMwanR1c3dRZW5UTkxqSHFWbDh1SXhrckpYMU1GZkdkMVNB?oc=5\" target=\"_blank\">Will Exiting Rocatinlimab Reshape Amgen's (AMGN) Immunology Focus and Broader R&amp;D Narrative?</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">simplywall.st</font>",
      "published": "2026-02-03T03:40:26+00:00",
      "source": "simplywall.st"
    },
    {
      "title": "AlphaQuest LLC Makes New Investment in Amgen Inc. $AMGN - MarketBeat",
      "link": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNOTNZdFpRNWREZXAzMXJTc3dKd3lzcUdEOVFqcFZ2a0JlTWpaRF85S3BvRWpKc2NtZlJOOEIwelVHOUVxR2J5ZXMtc0pkeElnV2dOTEJiTVhIdXh0U0g3OXpwdHdIeVRZd2RMTmJHcURFVUxicGlKdFBuMVFFZXBEWGwwbG1ZZm1IOENGdGJRZHdKTnIyYzZTVUljbV9VXzZCaWFaVzRtVHU3eldCSzR6eFk1UHM?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMitAFBVV95cUxNOTNZdFpRNWREZXAzMXJTc3dKd3lzcUdEOVFqcFZ2a0JlTWpaRF85S3BvRWpKc2NtZlJOOEIwelVHOUVxR2J5ZXMtc0pkeElnV2dOTEJiTVhIdXh0U0g3OXpwdHdIeVRZd2RMTmJHcURFVUxicGlKdFBuMVFFZXBEWGwwbG1ZZm1IOENGdGJRZHdKTnIyYzZTVUljbV9VXzZCaWFaVzRtVHU3eldCSzR6eFk1UHM?oc=5\" target=\"_blank\">AlphaQuest LLC Makes New Investment in Amgen Inc. $AMGN</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">MarketBeat</font>",
      "published": "2026-02-03T08:41:23+00:00",
      "source": "MarketBeat"
    },
    {
      "title": "How Patients and Supportive Care Partners Work Together to Turn Their World Right-Side-Up After a Cancer Diagnosis - Amgen",
      "link": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQRHAyN3FpdFV3Y3pvWi1DNWN3QkIzaHNWNFBPVlZEZW5oM3VuNGx0NjdDZFFqb1ljTzM1NGV6cktxcU9FUlVUcENzMVZHTW9YekpMdU5iVjVZSjRBeUhDdFdrNTdubVJsbnJJOGpJTTQtTkNCTVpoWTBreEQxeVRzeXhDX0pxQVZWUDZqd01yemJkVHFZenpNNTh0Z1UtampqWlRlZmRMZDQ0TEdGZEdrUUdvU2gzem1rcVYtc1Bmcl9LaFBPdzN5SDZ0WGRwT0hBYnNXZTJoVVhIa2hzejI2cGNuNkFON2c?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQRHAyN3FpdFV3Y3pvWi1DNWN3QkIzaHNWNFBPVlZEZW5oM3VuNGx0NjdDZFFqb1ljTzM1NGV6cktxcU9FUlVUcENzMVZHTW9YekpMdU5iVjVZSjRBeUhDdFdrNTdubVJsbnJJOGpJTTQtTkNCTVpoWTBreEQxeVRzeXhDX0pxQVZWUDZqd01yemJkVHFZenpNNTh0Z1UtampqWlRlZmRMZDQ0TEdGZEdrUUdvU2gzem1rcVYtc1Bmcl9LaFBPdzN5SDZ0WGRwT0hBYnNXZTJoVVhIa2hzejI2cGNuNkFON2c?oc=5\" target=\"_blank\">How Patients and Supportive Care Partners Work Together to Turn Their World Right-Side-Up After a Cancer Diagnosis</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Amgen</font>",
      "published": "2026-02-02T16:49:18+00:00",
      "source": "Amgen"
    }
  ],
  "product_launches": [
    {
      "title": "A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-10-16T07:00:00+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "A Look at Amgen’s (AMGN) Valuation Following FDA Nod Expanding Repatha’s Patient Reach - simplywall.st",
      "link": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNLXhOdjVpSkxmUXdQRVpHS2tPVUdGcG1EZHJFZDZpNzg5Y3pCT3FTdlVhNFR4MmhicGVQN0luNnNVMkZCOTF5NkR0WWlUOXVtMmtfbzBJWVE4dUlwbjFXX29sREp3enhLVkowNV9QbXd4UGtMTlJjd29PSHNPSUd3TkhJNm55T1AxRTdUazNkd0NHRThWMGtTZU44V3lidnR5UmQyMWZxd0FrcHVPTVlfWTJWQTFMTGRQRDZQcEtaSlc0TklGNzlMam1pRjhDVVVpc0ZRStIB2gFBVV95cUxOV1VkLV9BSGdmbmR6anpGRENtdVctYTJEUUxEdXVCZ25PUV9qbHVNMGoyOFdxSE00TGk3QV9uV3Z2d1hTS0VJaEpmMXNJUzhIZTNjX2JnNHYwN29fQldveUsyWjhQQkR6bDh6dElyZlRDa0dnTDNxN0pNS0xUdVZwdGxaNmZpVVdDNFJ4U1RuZ040dy1wZUJkTXNKbzBIMkZzMlJ2U1c1TEloTmtFUGx3ZERfcGFQQURKUDNWcFdWVzJYQzM5dExHc2ZNQ2czcFU5c1pwOUxoV0NFQQ?oc=5",
      "summary": "<a href=\"https://news.google.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?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation Following FDA Nod Expanding Repatha’s Patient Reach</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">simplywall.st</font>",
      "published": "2025-09-08T07:00:00+00:00",
      "source": "simplywall.st"
    },
    {
      "title": "Amgen History - Amgen",
      "link": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE53MklERTNSbkNVaXhYQ3dPcEtDRU1uTW5mLUdxSGFtZ0wxMmFZSlQ1SnZkY1hZOFZ1RmRsZjNXMGYtM1hQXzl0R0NJSmtQLVJnYzlN?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiU0FVX3lxTE53MklERTNSbkNVaXhYQ3dPcEtDRU1uTW5mLUdxSGFtZ0wxMmFZSlQ1SnZkY1hZOFZ1RmRsZjNXMGYtM1hQXzl0R0NJSmtQLVJnYzlN?oc=5\" target=\"_blank\">Amgen History</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Amgen</font>",
      "published": "2020-12-12T03:24:17+00:00",
      "source": "Amgen"
    },
    {
      "title": "3 major patent losses this year — and a key strategy to fill the gaps - Pharma Voice",
      "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPNGpDZTgwdDRLOFozTU9HVGVzWWpkS1dXSEd4X1c0RzVVdktmbzUwVVhWSW01X3BkbGl5c084anVWeHVkX1FEU1pEMm13ZW91WlBwNE5CQVVmYURaaEFOREx0dk1fTTJyT01lYW1ZVXBOV2ZXTTdFamNYc2FVbTAyazJOeEVnNkszUXphcjI5blNXSV9wZ0tmcThR?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimgFBVV95cUxPNGpDZTgwdDRLOFozTU9HVGVzWWpkS1dXSEd4X1c0RzVVdktmbzUwVVhWSW01X3BkbGl5c084anVWeHVkX1FEU1pEMm13ZW91WlBwNE5CQVVmYURaaEFOREx0dk1fTTJyT01lYW1ZVXBOV2ZXTTdFamNYc2FVbTAyazJOeEVnNkszUXphcjI5blNXSV9wZ0tmcThR?oc=5\" target=\"_blank\">3 major patent losses this year — and a key strategy to fill the gaps</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Pharma Voice</font>",
      "published": "2025-07-21T07:00:00+00:00",
      "source": "Pharma Voice"
    },
    {
      "title": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns - Seeking Alpha",
      "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5\" target=\"_blank\">Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Seeking Alpha</font>",
      "published": "2025-07-15T07:00:00+00:00",
      "source": "Seeking Alpha"
    }
  ],
  "stock": {
    "ticker": "AMGN",
    "currency": "USD",
    "latest": {
      "date": "2026-02-02",
      "close": 344.67999267578125
    },
    "history": [
      {
        "date": "2026-01-23",
        "close": 344.75
      },
      {
        "date": "2026-01-26",
        "close": 349.69000244140625
      },
      {
        "date": "2026-01-27",
        "close": 351.32000732421875
      },
      {
        "date": "2026-01-28",
        "close": 342.2200012207031
      },
      {
        "date": "2026-01-29",
        "close": 342.94000244140625
      },
      {
        "date": "2026-01-30",
        "close": 341.8800048828125
      },
      {
        "date": "2026-02-02",
        "close": 344.67999267578125
      }
    ],
    "name": "Amgen Inc."
  }
}